RemeGenix

RemeGenix is a biopharmaceutical company founded to develop disease-modifying therapies for Alzheimer's disease based on fundamental research from The Rockefeller University. The company's core focus is the modulation of the Gamma-secretase activating protein (GSAP), a target identified by Nobel laureate Dr. Paul Greengard as a specific regulator of amyloid-beta production. By developing small molecule inhibitors of GSAP, RemeGenix aimed to reduce toxic amyloid levels without interfering with the essential Notch signaling pathway, a major safety hurdle for earlier gamma-secretase inhibitors. Although the company was established with significant academic prestige and initial funding, it has not reported clinical progress or operational activity in recent years. Its approach remains a notable example of precision targeting within the amyloid hypothesis framework.